FDA reviews olmesartan safety record, cites CV deaths in trials - TheHeart.Org PDF Print
TheHeart.OrgThe primary end points of the two trials were dominated by measures of renal function. In the Randomized Olmesartan and Diabetes Microalbuminuria Prevention

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.